Laboratory Automation in Microbiology: Impact on Turnaround Time of Microbiological Samples in COVID Time.

Publication date: Jul 01, 2023

Laboratory Automation (LA) is an innovative technology that is currently available for microbiology laboratories. LA can be a game changer by revolutionizing laboratory workflows through efficiency improvement and is also effective in the organization and standardization of procedures, enabling staff requalification. It can provide an important return on investment (time spent redefining the workflow as well as direct costs of instrumentation) in the medium to long term. Here, we present our experience with the WASPLab system introduced in our lab during the COVID-19 pandemic. We evaluated the impact due to the system by comparing the TAT recorded on our samples before, during, and after LA introduction (from 2019 to 2021). We focused our attention on blood cultures (BCs) and biological fluid samples (BLs). TAT recorded over time showed a significant decrease: from 97 h to 53. 5 h (Δ43. 5 h) for BCs and from 73 h to 58 h (Δ20 h) for BLs. Despite the introduction of the WASPLab system, we have not been able to reduce the number of technical personnel units dedicated to the microbiology lab, but WASPLab has allowed us to direct some of the staff resources toward other laboratory activities, including those required by the pandemic. LA can significantly enhance laboratory performance and, due to the significant reduction in reporting time, can have an effective impact on clinical choices and therefore on patient outcomes. Therefore, the initial costs of LA adoption must be considered worthwhile.

Open Access PDF

Concepts Keywords
Efficiency enhance laboratory performance
Microbiology fast track
Pandemic laboratory workflows
Wasplab staff shortage
total lab automation
turn-around time


Type Source Name
disease VO time
disease VO efficiency
disease VO effective
disease VO organization
drug DRUGBANK Etoperidone
disease MESH COVID-19 pandemic
disease VO Tat
disease IDO blood
disease MESH Infectious Diseases
disease MESH Neurodegenerative Diseases
pathway REACTOME Neurodegenerative Diseases
drug DRUGBANK Coenzyme M
disease IDO susceptibility
disease MESH emergency
disease MESH malaria
pathway KEGG Malaria
disease VO protocol
drug DRUGBANK L-Phenylalanine
disease IDO colony
disease VO device
disease MESH uncertainty
disease VO company
disease IDO pathogen
disease VO USA
disease MESH critically ill
disease IDO assay
disease VO report
disease IDO process
disease VO efficient
disease IDO drug susceptibility
disease IDO site
disease IDO intervention
disease IDO cell

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *